Table 2.
Survival outcomes for (B)RPC patients treated with (m)FOLFIRINOX as first-line treatment with or without additional radiotherapy
| Study (reference) | No. of (B)RPC patients | Median FU, months | Baseline for OS and PFS calculations | Median OS, months (95% CI) | Median PFS, months (95% CI) | |
|---|---|---|---|---|---|---|
| All patients | Resected patients | Resected patients | ||||
| FOLFIRINOX alone | ||||||
| Barenboim22 | 23 | 17.0 | Start treatment | 27.9 (NR) | 34.3 (NR) | 13.7 (NR) |
| Dhir36 | 73a | 35.8 | Diagnosis | # | 38.7 (25.7–50.6) | NR |
| Okada23 | 10 | NR | NR | NR | NR | NR |
| Tinchon24 | 10 | 15.4 | Start treatment | Not reached | Not reached | Not reached |
| De Marsh34 | 21b | 27.7 | Start treatment | 34 (12.3-57.6) | 35.5 (15.0–59.2) | 15.2 (10.5–24.1) |
| Kim35 | 13c | 41.4c | Start treatment | # | 34.2 (NR)c | 19.6 (NR)c |
| Medrano25 | 121 | Mean 39 | Diagnosis | # | 45.0 (NR) | 28.0 (NR) |
| Yoo26 | 75 | 40.3 | Start treatment | 18.4 (16.1–20.8) | NR | NR |
| Estimated median survival (months) | 351 | 33.3 | 21.6 (range 18.4–34.0) | 40.4 (range 34.2–45.0) | 22.1 (range 13.7–28.0) | |
| FOLFIRINOX with radiotherapy | ||||||
| Christians27 | 18 | 22.0 | Diagnosis | 15.8 (NR)d | Not reached | NR |
| Katz28 | 22 | NR | Trial registration | 21.7 (15.7–not reached) | 23.1 (NR)d | At 12 months: 53% (33–86); At 18 months: 40% (19–84) |
| Murphy29 | 48 | 18.0 | Start treatment | 37.7 (19.4–not reached) | Not reached | 48.6 (14.4–not reached) |
| Shaib30 | 13 | 18.0 | Trial registration | 11.0 (5.8–not reached) | Not reached (9.3–not reached) | 29.6 (5.1–not reached) |
| Tran31 | 25 | NR | Trial registration | 24.4 (12.6–40.0) | 37.1 (15.4–not reached) | 21.6 (8.2–31.7) |
| Bolton32 | 31 | NR | Resection | # | 42.5 (NR)e | NR |
| Mahaseth33 | 4 | NR | Start treatment | NR | NR | NR |
| Estimated median survival (months) | 161 | 18.8 | 22.4 (range 11.0–37.7) | 33.5 (range 23.1–42.5) | 28.4 (range 18.0–48.6)f | |
(B)RPC resectable or borderline resectable pancreatic cancer, CI confidence interval, FU follow-up, No. number, NR not reported, OS overall survival, PFS progression-free survival
aIncluding upfront resectable pancreatic cancer (n = 15), bAll upfront resectable pancreatic cancer, cSurvival outcomes for subgroup of BRPC patients specifically, dEstimation based on Kaplan–Meier results, eBased on Kaplan–Meier results of BRPC patients who received 4 or more cycles of neoadjuvant FOLFIRINOX, with 3 months added for duration of neoadjuvant treatment and time to surgery, fPooled estimate including a median PFS of 18 months for Katz et al.,28 since the median PFS certainly did not exceed 18 months
#Study only included patients who underwent resection